Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
14(R,S)-[18F]fluoro-6-thia-heptadecanoic acid
- Development stage
- Unknown
- Lead developer
- Aarhus University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
14(R,S)-[18F]fluoro-6-thia-heptadecanoic acid ([18F]FTHA) is a radiolabeled long-chain fatty acid (LCFA) analog used as a positron emission tomography (PET) tracer to evaluate and quantify exogenous free fatty acid (FFA) uptake and utilization (beta-oxidation) in vivo. Developed as a metabolically trapped tracer, [18F]FTHA enters cells via the same transport mechanisms as natural fatty acids and undergoes initial mitochondrial beta-oxidation steps before becoming trapped in the tissue due to its sulfur atom at the sixth carbon position. It is widely utilized in clinical and preclinical research to study myocardial, skeletal muscle, liver, and adipose tissue fatty acid metabolism in metabolic conditions such as obesity, type 2 diabetes, and pre-diabetes, as well as to visualize abdominothoracic lymphatic drainage and thoracic duct flow.
- Other names
- 14(R,S)-18F-fluoro-6-thia-heptadecanoic acid14(R,S)-[18F]fluoro-6-thiaheptadecanoic acid18F-FTHA[18F]FTHAfluorine-18-fluoro-6-thia-heptadecanoic acidfluorine18-fluoro-6-thia-heptadecanoic acidfluorine 18-fluoro-6-thia-heptadecanoic acidFTHA
02
Targets
SLC7A1 (Cationic amino acid transporter 1)ACS (Acetyl-CoA synthetase)CD36 (CD36 antigen)
Beyond the preview
Go deeper on 14(R,S)-[18F]fluoro-6-thia-heptadecanoic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 14(R,S)-[18F]fluoro-6-thia-heptadecanoic acid.